A secondary analysis of the phase 3 KEYNOTE-716 trial evaluates whether adjuvant pembrolizumab alters the risk of subsequent cutaneous malignancies in patients with resected stage IIB or IIC melanoma, while...
For oncologists considering immunotherapy sequencing, a Nature report from MD Anderson Cancer Center in Houston, TX, suggests that receipt of a SARS-CoV-2 mRNA vaccine near the start of immune checkpoint...
A decade-long follow-up of a landmark trial examining survival outcomes in patients with advanced melanoma treated with nivolumab plus ipilimumab, nivolumab monotherapy, or ipilimumab monotherapy, provides...
Patients with melanoma and who are being treated with PD-1 inhibitors have an increased risk of experiencing immune-related neurologic adverse events, compared with patients who are not being treated with...
In a multicenter, randomized, open-label, phase 3 trial, researchers set out to determine whether an advanced surgical therapy, isolated hepatic perfusion, could improve outcomes among previously untreated...
Researchers determined the impact of melanoma subtypes on cutaneous immune-related adverse events and survival among those who received immune checkpoint inhibitor therapy.
In a recent study, researchers evaluated the association between renal transplantation and risk of melanoma. Also evaluated were other risk factors for developing melanoma in this patient population.
The FDA has expanded the approval of an intravenous injection for the treatment of metastatic or unresectable melanoma to include use in pediatric patients.
In a recent study, researchers compared the efficacy of nivolumab with chemotherapy on clinical outcomes among patients with melanoma that progressed following ipilimumab therapy.
